KLK4, Kallikrein-4, Prostase, KLK-L1, EMSP1, PRSS17, PSTS
Recombinant Human KLK4 /Kallikrein-4 Protein (rhKallikrein-4 /KLK4) Ser 27 - Ser 254 (Accession # AAH69429) was produced in human 293 cells (HEK293) at ACRObiosystems.
rhKallikrein-4 /KLK4, fused with 6×His tag at the C-terminus, has a calculated MW of 25.2 kDa. The predicted N-terminus is Ser 27. DTT-reduced Protein migrates as 30-32 kDa due to glycosylation.
Less than 1.0 EU per μg of the rhKallikrein-4 /KLK4 by the LAL method.
>92% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH 7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
Kallikrein-4 (KLK4) is also known as Enamel matrix serine proteinase 1 (EMSP1), Kallikrein-like protein 1 (KLK-L1), Prostase, Serine protease 17 (PRSS17), PSTS, which belongs to the peptidase S1 family and Kallikrein subfamily. KLK4 contains one peptidase S1 domain. KLK4 is expressed in prostate and involved in enamel formation. Defects in Kallikrein-4 / KLK4 are the cause of amelogenesis imperfecta hypomaturation type 2A1 (AI2A1) which is an autosomal recessive defect of enamel formation. The disorder involves both primary and secondary dentitions.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.